Evolving Considerations in the Treatment
and Management of Metastatic Melanoma: Expert Strategies on Immune
A continuing medical education
activity provided by NAMCP and AAMCN
This activity is an archive of the live session from the 2021 Spring
Managed Care Forum.
If you participated in the live session, you are not eligible for
continuing education credits from this archive.
This activity is valid from May 1, 2021 through August 1, 2022
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Merck Sharp & Dohme Corp.
Melanoma is the most serious type of skin cancer. It will be found
in approximately 73,870 people in the US in 2020 according to the
National Cancer Institute. While it is the least common amongst skin
cancers, it is by far the most deadly, with 9,940 people expected to
die in 2020. Both of those numbers have been rising in recent years.
Fortunately for patients with metastatic melanoma, significant
progress has been made in the treatment of this deadly disease over
the past few years, especially in the area of immunotherapies. This
webinar on recent advances in the treatment and management of
metastatic melanoma will provide attendees with updated treatment
strategies, guidelines, and successful evidence-based treatment
approaches from recent clinical data.
Upon completion of this
activity, participants will be able to:
Assess strategies to properly
identify patients for neoadjuvant and adjuvant systemic
therapies in resectable melanoma
Evaluate recent safety and efficacy
data regarding immunotherapy as single-agent or in combination
strategies in the treatment of melanoma
Apply recent data and new
therapeutic options to clinical scenarios in the treatment of
Identify adverse events and
appropriate management strategies associated with immunotherapy
treatment of melanoma
Assess the managed care
considerations of immune checkpoint inhibitors, including
combination, by exploring where these agents fit in the melanoma
||Sanjiv S. Agarwala, MD
Temple University School of Medicine
Agarwala has no financial relationships with ineligible
companies to disclose.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue